Evidence that estrogens inhibit LH secretion through opioids in postmenopausal women using naloxone.
To evaluate whether ovarian steroid environment may modify endogenous opioid activity at hypothalamic-pituitary level, the effects of naloxone infusion (1.2 mg/h for 4 h) on gonadotropin secretion were studied in 5 postmenopausal women who had natural menopause 3-5 years before the study. In addition, naloxone infusion was repeated in the same subjects after chronic oral treatment with conjugated estrogens (1.25 mg/day in two divided doses for 20 days). Before treatment, both the circulating levels of estrogens and plasma gonadotropins were in the normal range for postmenopausal women and naloxone infusion did not induce any significant modification of gonadotropin secretion. In contrast, after estrogen therapy, and the consequent rise in estrogen plasma levels, naloxone infusion induced a significant LH increase (p less than 0.01) starting during the last hour of treatment. These findings seem to confirm that endogenous opioid peptides may modulate the inhibitory effect exerted by estrogens on LH secretion, in humans.
D004723:Endorphins / Q000502:physiology*; D004967:Estrogens / Q000097:blood / Q000502:physiology*; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism*; D008593:Menopause; D008875:Middle Aged; D009270:Naloxone
D004723:Endorphins; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D009270:Naloxone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone